Calcium/calmodulin-dependent protein kinase type II subunit alpha
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Calcium/calmodulin-dependent protein kinase type II subunit alpha as ChEMBL target CHEMBL2359, mapped to UniProt P11275. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Calcium/calmodulin-dependent protein kinase type II subunit alpha matters
Calcium/calmodulin-dependent protein kinase type II subunit alpha is reviewed as Calcium/calmodulin-dependent protein kinase type II subunit alpha (UniProt P11275); the current evidence base includes 2 approved drugs, 41 compounds, and 10 assays, with lead potency reaching pChEMBL 9.9.
Calcium/calmodulin-dependent protein kinase type II subunit alpha Sequence length is 478 aa.
Review this target as Calcium/calmodulin-dependent protein kinase type II subunit alpha, mapped to UniProt P11275. Sequence length is 478 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 2 approved drugs, 41 compounds, and 10 assays for this target. The dominant activity type is KI. CHEMBL190035 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL190035 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Calcium/calmodulin-dependent protein kinase type II subunit alpha matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P11275, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL190035
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL240714
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL5206854
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL1031
|
7.7 | Ki | — |
|
|
No preferred name
CHEMBL5175277
|
7.7 | Ki | — |